ConductScience.org, home

Comparison · NCT05966129-sae

Acute Pain - Immediate PGx Testing vs Acute Pain - Delayed PGx Testing: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Acute Pain - Immediate PGx Testing vs Acute Pain - Delayed PGx Testing: serious adverse events. Trial comparisons, record NCT05966129-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05966129-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.00477wilson
Risk in group 2000.00477wilson
Risk difference, group 1 minus group 20-0.004770.00477newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Acute Pain - Immediate PGx Testing
Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider~Pharmacogenetic testing: Genetic testing of CYP2D6 and CYP2C19~Clinical decisions support: Prescribing recommendations to the provider based on the pharmacogenetic testing results
0801EG000
Group 2Acute Pain - Delayed PGx TestingDelayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period~Pharmacogenetic testing: Genetic testing of CYP2D6 and CYP2C190801EG001

Harm

What it counts
Total, serious adverse events
Time frame

Source ClinicalTrials.gov

Trial

Title
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)
NCT number
NCT05966129
Phases
NA
Conditions
Acute Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Lead sponsor
Duke University
Results first posted
2025-06-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05966129-sae